Mizuho reissued their sell rating on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a report published on Tuesday. The firm currently has a $7.00 target price on the specialty pharmaceutical company’s stock, down from their prior target price of $8.00.

Other equities research analysts have also issued research reports about the stock. Jefferies Group LLC set a $18.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a buy rating in a research note on Saturday, May 6th. Stifel Nicolaus reiterated a buy rating and issued a $45.00 target price on shares of Valeant Pharmaceuticals International in a report on Wednesday, May 10th. Vetr downgraded shares of Valeant Pharmaceuticals International from a strong-buy rating to a buy rating and set a $14.94 target price on the stock. in a report on Monday, May 15th. Guggenheim began coverage on shares of Valeant Pharmaceuticals International in a report on Saturday, June 17th. They issued a buy rating and a $18.00 target price on the stock. Finally, BidaskClub upgraded shares of Valeant Pharmaceuticals International from a hold rating to a buy rating in a report on Thursday, June 29th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of $17.67.

Shares of Valeant Pharmaceuticals International (VRX) opened at 13.33 on Tuesday. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $31.84. The company has a 50-day moving average price of $15.39 and a 200 day moving average price of $13.36. The firm’s market capitalization is $4.65 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The business had revenue of $2.23 billion during the quarter, compared to analyst estimates of $2.23 billion. During the same quarter in the previous year, the business earned ($0.88) EPS. Valeant Pharmaceuticals International’s quarterly revenue was down 7.7% compared to the same quarter last year. Analysts expect that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/09/02/valeant-pharmaceuticals-international-inc-vrx-rating-reiterated-by-mizuho.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The stock was acquired at an average cost of $14.33 per share, with a total value of $143,300.00. Following the completion of the purchase, the director now directly owns 77,479 shares in the company, valued at approximately $1,110,274.07. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 5.87% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. ValueAct Holdings L.P. increased its stake in shares of Valeant Pharmaceuticals International by 20.0% in the first quarter. ValueAct Holdings L.P. now owns 17,997,224 shares of the specialty pharmaceutical company’s stock valued at $198,509,000 after buying an additional 3,002,963 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Valeant Pharmaceuticals International during the second quarter valued at approximately $41,574,000. Canada Pension Plan Investment Board increased its stake in shares of Valeant Pharmaceuticals International by 24,953.6% in the second quarter. Canada Pension Plan Investment Board now owns 2,104,500 shares of the specialty pharmaceutical company’s stock valued at $36,525,000 after buying an additional 2,096,100 shares during the last quarter. Saba Capital Management L.P. increased its stake in shares of Valeant Pharmaceuticals International by 132.4% in the first quarter. Saba Capital Management L.P. now owns 2,315,900 shares of the specialty pharmaceutical company’s stock valued at $25,544,000 after buying an additional 1,319,311 shares during the last quarter. Finally, Cannell Peter B & Co. Inc. purchased a new stake in shares of Valeant Pharmaceuticals International during the second quarter valued at approximately $20,981,000. 50.49% of the stock is owned by hedge funds and other institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.